IP Verse

Chimeric Antigen Receptors Targeting B-Cell Maturation Antigen

Patent No. EP3689383 (titled "Chimeric Antigen Receptors Targeting B-Cell Maturation Antigen") was filed by The United States OF America on Mar 15, 2013. The application was issued on Dec 31, 2025.

Patent Summary

A pharmaceutical composition comprising T-cells engineered to express a chimeric antigen receptor (CAR) that targets B-cell Maturation Antigen (BCMA) for the treatment of multiple myeloma. The CAR comprises an antigen recognition moiety directed against BCMA and a T-cell activation moiety that includes a transmembrane domain and an intracellular signaling domain. The composition is administered to patients with multiple myeloma to induce antigen-specific T-cell responses against BCMA-expressing cancer cells.

UPC Cases New

Latest UPC cases involving this patent.

Case NumberFiling DatePlaintiffProceeding Type
UPC_CFI_0000029/2026Jan 5, 20262Seventy BIOInfringement

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BOULT WADE TENNANTDec 31, 2025BOULT WADE TENNANT

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3689383

THE UNITED STATES OF AMERICA
Application Number
EP19216091A
Filing Date
Mar 15, 2013
Status
Granted And Under Opposition
Nov 28, 2025
Publication Date
Dec 31, 2025
External Links
Slate, Register , Google Patents